Developing innovative neuroprotection therapies for Traumatic Brain Injuries (TBI), concussions, stroke, and neurodegenerative disorders, Astrocyte Pharmaceuticals Inc. is organized around clinically proving the neuro-protective benefits of selective astrocyte activation and advancing breakthrough therapeutic agents for treating brain injury patients accelerating the recovery and well-being of brain injury patients: stroke, TBI, concussion, and neurodegenerative disorders such as Alzheimerâs disease. The companyâs lead program AST-004 is a novel small molecule candidate currently undergoing dose optimization, with confirmation of the clinical development candidate and initiation of regulatory preclinical toxicology studies being undertaken. The product would be administered by intravenous injection by emergency responders or a medical professional within 24 hours of injury to limit neuronal damage and cell death, The Astrocyte Pharmaceuticals approach differs significantly from historical neuroprotective attempts inthe fact that the firm is focused on a non-neuronal cell type, astrocytes, which are the most common cell type in the human brain and have only recently received broader attention as important cellular targets for therapeutic research. Additionally, as astrocytes are the natural caretaker cells in the brain and their activation, as our data show, enhances multiple natural healing mechanisms including protection against edema, glutamate excitotoxicity and oxidative str
